2 results
Approved WMOCompleted
Primary Objective To determine whether the combination of Onartuzumab + * erlotinib is superior (in terms of OS) to placebo * erlotinib after standard platinum-based chemotherapy in patients with Met diagnostic*positive non*small cell lung cancer (…
Approved WMOCompleted
Primary objective: Estimate the MTD and/or RDE of LDK378 as a single agent when administered orally to pediatric patients with ALK-activated tumors in the fasted and in fed stateSecondary objectives: Objective 1: Characterize the safety and…